The SCE Medical Oncology sits twice per year — February and September. The oncology landscape evolves faster than any other medical specialty — new immunotherapy indications, new targeted agents, and new NICE technology appraisals appear continuously. A question bank for oncology that is not updated regularly becomes outdated within months.
The update problem
Oncology guidelines are not static. A PD-L1 inhibitor approved for first-line NSCLC in 2024 may have expanded indications by 2026. A NICE technology appraisal published in January may change prescribing practice by March. The exam tests current guidelines — not the guidelines from when your question bank was written.
This creates a structural disadvantage for providers who write questions once and do not update them. A Cardiology bank written in 2023 may still be mostly accurate in 2026 because ESC heart failure management has not fundamentally changed. An Oncology bank written in 2023 may have dozens of outdated questions because the NICE TA landscape, immunotherapy indications, and biomarker-driven treatment algorithms have shifted substantially.
StudyPRN
StudyPRN's Medical Oncology bank contains approximately 495 questions. This is one of their smaller specialty banks. The content covers the major tumour sites — breast, lung, colorectal, urological, gynaecological — and includes oncological emergencies. The update frequency is not publicly documented.
Pricing follows the standard model. Standard limitations apply.
iatroX
iatroX's SCE Medical Oncology bank contains over 1,500 questions covering all major tumour sites at the JRCPTB curriculum weighting — breast (14 per cent), lung (14 per cent), GI cancers including oesophageal, gastric, colorectal, pancreatic, and HCC (14 per cent), urological (8 per cent), gynaecological (8 per cent), melanoma (6 per cent), and the remaining sites.
Immunotherapy and targeted therapy content is substantial — mechanism of action, biomarker-driven selection (PD-L1 TPS, EGFR mutations, ALK rearrangements, HER2 status, BRCA mutations, MSI status), immune-related adverse event recognition and management (colitis, hepatitis, pneumonitis, endocrinopathies, neurological irAEs), and the specific management algorithms for each irAE grade. The exam tests irAE management in detail because these are the clinical decisions that oncology registrars make daily.
NICE technology appraisal access criteria are covered for each agent — what biomarker criteria must be met, what line of therapy the drug is approved for, and what performance status requirements apply. These are the real-world prescribing constraints that the exam tests.
Oncological emergency content covers neutropenic sepsis (door-to-needle antibiotics), spinal cord compression (dexamethasone and urgent MRI), SVCO, tumour lysis syndrome, and hypercalcaemia of malignancy.
All included at £29 per month or £99 per year.